Myotonic dystrophy is a genetic disorder characterized by myotonia and two forms: DM1 and DM2, with DM2 featuring fewer systemic symptoms and a better prognosis. Patients typically exhibit muscle weakness, facial changes, and cataracts, with treatment focusing on genetic counseling and symptomatic management. Chronic progressive external ophthalmoplegia and neurocutaneous syndromes, including neurofibromatosis, present additional ocular and systemic complications requiring further investigation and management.